Total cases |
28 |
Age (years)
Mean ± SD
Median (range)
|
8.79 ± 5.03
7 (3.5-18)
|
Gender, n (%)
Male
Female
|
15 (53.6%)
13 (46.4%)
|
Underlying disease, n (%)
ALL
AML
|
19 (67.9%)
9 (32.1%)
|
Status of underlying disease, n (%)
Remission
Relaps
|
7 (25%)
21 (75%)
|
Prophylactic agent before IFI onset, n (%)
Flucanazole
Voriconazole
|
26 (92.8%)
2 (7.2%)
|
Prophylaxis duration before IFI episodes (days)
Mean ± SD (range)
|
47 ± 24.04 (30-84)
|
Duration of neutropenia at IFI onset (days)*
Mean ± SD (range)
in ALL
in AML
|
42.87 ± 35.5 (7-140)
42.18 ± 40.1 (7-140)
44.75 ± 20 (20-64)
|
IFI classification, episode (%)
Possible
Probable
Proven
|
26 (78.8%)
5 (15.1%)
2 (6.1%)
|